26S proteasome Inhibitors
1 drugsAbout 26S proteasome
The 26S proteasome is a large protein complex responsible for degrading damaged or unnecessary proteins, maintaining cellular homeostasis. Its proteolytic function makes it a valuable drug target, particularly in oncology, by disrupting protein degradation and inducing cell death.
Inhibiting the 26S proteasome disrupts protein degradation, leading to an accumulation of misfolded proteins and cell death, especially in cancer cells. Currently, there is no genetic evidence data available linking the 26S proteasome to specific diseases.
There is one FDA-approved drug, VELCADE (Takeda), a small molecule targeting the 26S proteasome for oncology indications. VELCADE was first approved in 2003 and remains the only approved drug for this target.
Top 26S proteasome Drugs
Takeda is the only company with an approved drug targeting the 26S proteasome.
The market is highly concentrated, suggesting high entry barriers or limited commercial opportunity.
26S proteasome Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 26S proteasome, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
26S proteasome Clinical Trials 519 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on 26S proteasome. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 155 | 90 | 38 | 27 | 70% |
| Phase 2 | 251 | 124 | 65 | 62 | 66% |
| Phase 3 | 99 | 39 | 6 | 54 | 87% |
| Phase 4 | 14 | 6 | 4 | 4 | 60% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved 26S proteasome drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting 26S proteasome. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
26S proteasome Drug Approval Timeline (2003 - 2003)
VELCADE was approved in 2003 and remains the only approved drug.
The approval timeline suggests potential saturation or challenges in developing new drugs for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 228 (54 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on 26S proteasome. A trial counts if an approved drug acting on 26S proteasome is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.